Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
Estimate the hazard ratio for progression free survival (PFS) duration in patients with previously untreated advanced stage NSCLC for the combination of erlotinib plus bevacizumab relative to the combination of standard platinum based chemotherapy plus bevacizumab.
Inclusion criteria
- Advanced Non-Small-Cell-Lung-Cancer (Stage IIIb and IV) 1st line